3D-EQA27035 - tenofovir-related-compound-2
Es wurde leider kein Produkt mit der Referenz 3D-EQA27035 gefunden, aber bitte schauen Sie sich die folgenden ähnlichen Produkte an:
(R)-(-)-9-(2-Hydroxypropyl)adenine
CAS:Formel:C8H11N5OReinheit:97%Farbe und Form:SolidMolekulargewicht:193.20589-(1E)-1-Propen-1-yl-9H-purin-6-amine
CAS:Formel:C8H9N5Reinheit:98%Farbe und Form:SolidMolekulargewicht:175.1906Tenofovir Disoproxil Related Compound B (10 mg) ((E)-9-(Prop-1-enyl)-9H-purin-6-amine)
CAS:Formel:C8H9N5Reinheit:98%Farbe und Form:SolidMolekulargewicht:175.1906Tenofovir Soproxil (((((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(hydroxy)phosphoryl)oxy)methyl isopropyl carbonate)
CAS:Compounds containing a pyrimidine ring, whether or not hydrogenated, or piperazine ring in the structure, nesoiFormel:C14H22N5O7PFarbe und Form:White Off-White SolidMolekulargewicht:403.125692,4,7-Trioxa-5-phosphanonanoic acid, 9-(6-amino-9H-purin-9-yl)-5-hydroxy-8-methyl-, 1-methylethyl ester, 5-oxide, (8R)-
CAS:Formel:C14H22N5O7PReinheit:98%Farbe und Form:SolidMolekulargewicht:403.3275Tenofovir Impurity 132
CAS:Formel:C14H22N5O7PFarbe und Form:White To Off-White SolidMolekulargewicht:403.33Mono-POC Tenofovir
CAS:Stability Hygroscopic
Applications An impurity of Tenofovir Disoproxil (T018505(P)), which is an acyclic phosphonate nucleotide analogue; reverse transcriptase inhibitor. It is used as an anti-HIV agent and an antiviral.
References Gan, L., et al.: Drug Metab. Dispos., 24, 344 (1996), Annaert, P., et al.: Pharm. Res., 14, 492 (1997), Naesens, L., et al.: Antimicrob. Agents Chemother., 42, 1568 (1998), Shaw, J. P., et al.: Pharm. Res., 14, 1824 (1997), Wyles, D., et al.: Clin Infect. Dis., 40, 174 (2005), Peng, J., et al.: J. Clin. Pharmacol., 46, 265 (2006), Seminari, E., et al.: J. Antimicrob. Chemother., 60, 831 (2007)Formel:C14H22N5O7PFarbe und Form:White To Light BeigeMolekulargewicht:403.33Tenofovir isoproxil monoester
CAS:Tenofovir isoproxil monoester is a prodrug of Tenofovir, which is an antiviral drug. Tenofovir prevents the growth of HIV by interfering with the synthesis of viral DNA. The process development stage involves converting Tenofovir to its disoproxil monoester form, which has been shown to have greater antiviral activity than Tenofovir alone. This conversion process involves condensing one molecule of fumarate with two molecules of tenofovir, forming tenofovir disoproxil fumarate (TFD). TFD can be converted back to Tenofovir using hydrolysis and hydrogenation. Impurities in TFD include isopropyl tenofovir and unidentified impurities that are not present in the parent drug, tenofovir. Tenofovir Disoproxil Fumarate was also shown to be more potent than TFD and is undergoing clinical trials forFormel:C14H22N5O7PReinheit:Min. 97 Area-%Farbe und Form:White/Off-White SolidMolekulargewicht:403.33 g/mol
